Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/8/2025

Metronidazole in Empyema Treatment

Rationale for Metronidazole Use

  • Anaerobic organisms are frequently involved in pleural infections, particularly in community-acquired empyema, necessitating coverage with agents like metronidazole, as recommended by the British Thoracic Society 1, 2
  • A significant proportion of both aerobes and anaerobes isolated from pleuropulmonary infections may be resistant to penicillin alone, making additional anaerobic coverage important, according to the British Thoracic Society 1
  • Metronidazole provides targeted coverage against anaerobic bacteria that are commonly present in mixed pleural infections, although the strength of evidence is moderate 3
  • For community-acquired empyema, the British Thoracic Society recommends cefuroxime 1.5g three times daily IV + metronidazole 400mg three times daily orally, with a strength of evidence rated as high 2
  • For community-acquired empyema, alternative regimens include benzyl penicillin 1.2g four times daily IV + ciprofloxacin 400mg twice daily IV, and meropenem 1g three times daily IV + metronidazole 400mg three times daily orally, both with a strength of evidence rated as moderate 2
  • For hospital-acquired empyema, piperacillin + tazobactam 4.5g four times daily IV is recommended, with a strength of evidence rated as high 2

Important Clinical Considerations

  • Aminoglycosides should be avoided in empyema treatment as they have poor penetration into the pleural space and may be inactive in acidic pleural fluid, according to the British Thoracic Society 2
  • Beta-lactams (penicillins and cephalosporins) show good penetration into the pleural space and remain the drugs of choice when combined with metronidazole for anaerobic coverage, with a strength of evidence rated as high 1
  • Clindamycin can be used as a single agent in penicillin-allergic patients as it provides both aerobic and anaerobic coverage, with a strength of evidence rated as moderate 4, 5

Special Populations

  • In children with empyema, metronidazole should be considered for older children to cover Fusobacterium unless co-amoxiclav or clindamycin are used, according to the British Thoracic Society 4, 5
  • For aspiration-related empyema, anaerobic coverage with metronidazole is particularly important, with a strength of evidence rated as moderate 4

Treatment Monitoring

  • Antibiotic therapy should be guided by pleural fluid culture results whenever possible, with a strength of evidence rated as high 1, 2
  • Surgical consultation should be considered after approximately 7 days in any patient not improving with drainage and antibiotics, according to the British Thoracic Society 2